Nasus Pharma (NYSEAM:NSRX) Update / briefing Transcript

Summary of Nasus Pharma Conference Call Company Overview - Company: Nasus Pharma - Product: NS002, an intranasal powder epinephrine product candidate designed to treat anaphylaxis - Technology: Proprietary powder technology called Nasax, which enhances drug absorption compared to traditional liquid formulations [2][3] Industry Context - Current Standard of Care: Epinephrine intramuscular auto-injectors (e.g., EpiPen) are commonly used for anaphylaxis treatment, but many patients do not carry them due to needle phobia and device bulkiness [4] - Market Research Insights: 90% of allergists prioritize speed of onset when prescribing epinephrine products, with 87% considering T100 (time to therapeutic threshold) clinically meaningful [4][5] Key Findings from Phase 2 Study - Study Design: Involved 50 healthy adults with allergic rhinitis, assessing NS002 under normal conditions and nasal congestion [6] - Pharmacokinetic Results: - NS002 achieved T100 in a median of 1.69 minutes compared to 3.42 minutes for EpiPen, indicating a statistically significant improvement [9][12] - At 2.5 minutes, 67% of NS002 subjects reached the therapeutic threshold versus 27% for EpiPen; at 5 minutes, 88% for NS002 versus 64% for EpiPen [10][12] - NS002 demonstrated 60% higher total epinephrine absorption in the critical 10-minute window compared to EpiPen [13] - Safety Profile: NS002 was well-tolerated with no serious adverse events reported; most adverse events were mild and self-resolving [11][13] Competitive Advantages - Speed of Onset: NS002's rapid absorption is crucial for emergency situations, potentially reducing the need for repeat doses [8][11] - Device Design: NS002 is a compact, needle-free device that is easy to carry, enhancing patient convenience and compliance [4][54] - Shelf Life: The dry powder formulation offers enhanced stability and longer shelf life compared to liquid formulations [54] Future Development Plans - Pivotal Study: Planned for initiation in Q4 2026, with top-line data expected by Q1 2027; will include comparisons to EpiPen and intramuscular adrenaline [15][39][56] - Regulatory Strategy: The company aims to submit an NDA in the second half of 2027, focusing on demonstrating comparability to EpiPen for FDA approval [39][48] Market Potential - Physician Acceptance: There is openness among allergists to switch patients to needle-free options, indicating potential market uptake for NS002 [18] - Best-in-Class Potential: The company believes NS002 could be a best-in-class treatment based on its pharmacokinetic profile and performance compared to existing products [23][24] Additional Considerations - Publication Plans: The company intends to publish study data in a peer-reviewed journal and present at major allergy conferences [30][31] - Comparative Analysis: While comparisons to other products like Neffy were discussed, the focus remains on NS002's superior profile based on available data [37] This summary encapsulates the critical insights and developments discussed during the conference call, highlighting the potential of Nasus Pharma's NS002 in the anaphylaxis treatment landscape.